Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells $230,200.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) SVP Amy Bachrodt sold 5,000 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $46.04, for a total value of $230,200.00. Following the transaction, the senior vice president directly owned 12,965 shares of the company’s stock, valued at $596,908.60. The trade was a 27.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amy Bachrodt also recently made the following trade(s):

• On Thursday, January 22nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $45.52, for a total value of $227,600.00.
• On Friday, January 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $39.15, for a total value of $195,750.00.
• On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.58, for a total value of $405,800.00.
• On Tuesday, December 30th, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.08, for a total transaction of $200,400.00.

Maze Therapeutics Stock Up 2.5%

Maze Therapeutics stock opened at $45.03 on Friday. The company has a fifty day simple moving average of $41.74 and a 200-day simple moving average of $30.01. The firm has a market capitalization of $2.17 billion and a price-to-earnings ratio of -2.15. Maze Therapeutics, Inc. has a 52-week low of $6.71 and a 52-week high of $49.25.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on MAZE. BTIG Research upped their price target on Maze Therapeutics from $37.00 to $46.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Wedbush raised their target price on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Guggenheim reiterated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Friday, December 19th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Finally, Wells Fargo & Company assumed coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They set an “overweight” rating and a $55.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Maze Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $44.50.

Institutional Trading of Maze Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of MAZE. Vanguard Group Inc. lifted its position in Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after buying an additional 915,342 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Maze Therapeutics by 3,868.5% in the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after acquiring an additional 758,104 shares during the last quarter. ArrowMark Colorado Holdings LLC acquired a new position in shares of Maze Therapeutics in the 3rd quarter worth approximately $14,135,000. Frazier Life Sciences Management L.P. boosted its position in shares of Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after purchasing an additional 438,274 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in Maze Therapeutics in the 3rd quarter valued at approximately $11,246,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.